This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rochester, C. D. Articles by Cooke, C. E. Search for Related Content Social Bookmarking                         What's this?

The Changing Face of Dyslipidemia Therapies

Department of Pharmacy Practice and Science; University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201; crochest{at}rx.umaryland.edu

Catherine E. Cooke, PharmD, BCPS, PAHM

Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore

To date, the major emphasis of dyslipidemia management has focused on the reduction of serum low-density lipoprotein cholesterol (LDL-C) levels, which several robust trials show significantly decreases the risk of coronory heart disease (CHD). To achieve goal LDL-C levels will require that some individuals take more than 1 cholesterol-lowering medication. In addition, many dyslipidemic patients also have concomitant risk factors for cardiovascular disease including hypertension, elevated plasma glucose, and high body mass index, requiring additional therapies. In addition to drugs that lower LDL-C, several agents under investigation are targeting other markers for decreasing the risk of atherosclerotic disease. Some of these agents target the reduction of C-reactive protein with a more potent statin, increased high-density lipoprotein cholesterol (HDL-C) with the cholesterol ester transfer protein inhibitor, inhibition of triglyceride or very-low-density lipoprotein cholesterol (VLDL-C) with the acyl coenzyme A: cholesterol acyltransferase inhibitor, reduction of VLDL-C with microsomal triglyceride transfer protein inhibitor, change in percentage coronary atheroma volume with HDL-C mimetics, and the reduction of bile acid transport and reabsorption with the ileal bile acid transport inhibitors. This review will provide an overview of the existing landscape for the medical treatment of dyslipidemia, including available therapies and future trends.

Key Words: Dyslipidemic or antilipidemic therapies • dyslipidemia or hyperlipidemia • coronary heart disease • atherosclerosis

Journal of Pharmacy Practice, Vol. 19, No. 2, 79-93 (2006)
DOI: 10.1177/0897190006290137


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?